IP Library Granted Patent US 10,987,325
Granted Patent B2
US 10,987,325 · App. 16/334,966 · Granted Apr 27, 2021

Compositions and uses thereof for treating inflammatory diseases and probiotic compositions

Inventors: Benjamin Bradley (Greater London, GB); Edward Green (Greater London, GB); Daniela Heeg (Greater London, GB)
Assignee: CHAIN Biotechnology Limited
A61K31/19A23K10/18A23L33/135A61K9/0056A61K9/50A61K35/742A61P1/00A61P29/00A23V2002/00A61K2035/115
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,987,325
App. No.
16/334,966
Granted
Apr 27, 2021
Kind
B2
Abstract

The invention relates to compositions and uses thereof in methods for treating an inflammatory disease, disorder or condition in a subject, in particular an inflammatory disease, disorder or condition of the digestive tract such as inflammatory bowel disease (IBD) and/or colorectal cancer. The invention also relates to probiotic compositions and the use of the compositions for treating gastrointestinal disorders.

Claims (13)

1. A composition comprising genetically engineered anaerobic bacteria that produce 3-hydroxybutyrate (3-HB), and an orally ingestible solid carrier, for delivering 3-HB to the lumen of the GI tract.

2. A composition according to claim 1 , wherein the bacteria comprise a non-native gene capable of expressing (R)-3-hydroxybutyryl-CoA dehydrogenase.

3. A composition according to claim 1 , wherein the bacteria are Clostridia bacteria, bacteria from cluster I, IV and/or XIVa of Clostridia, bacteria from the Clostridium genus or Clostridium butyricum.

4. A composition according to claim 1 , wherein the bacteria have native genes encoding phosphotransbutyrylase and/or butyrate kinase.

5. A composition according to claim 1 , wherein the bacteria produce (R)-3-hydroxybutyrate as the sole fermentation product or produce (R)-3-hydroxybutyrate in combination with acetate and/or butyrate as fermentation products.

6. A composition according to claim 1 further comprising a pharmaceutically acceptable carrier for use as a medicament.

7. A composition according to claim 1 for use in treating an inflammatory disease; for use in treating a gastrointestinal disorder; for use in treating gastrointestinal dysbiosis; for use in treating C. difficile infection; for use in modulating gut flora; or for use in animal feed.

8. A composition according to claim 7 , wherein the inflammatory disease or gastrointestinal disorder is inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, Pouchitis, Diverticulitis, ulcerative colitis, or colon cancer.

9. A composition according to claim 1 for use in food products.

10. A composition according to claim 9 , wherein the food product is a beverage, a drink a food supplement, or a nutraceutical.

11. A composition according to claim 1 , wherein the genetically engineered anaerobic bacteria produce (R)-3-hyroxybutyrate ((R)-3-HB).

12. A composition according to claim 1 , wherein the bacteria naturally produce butyrate.

13. A composition according to claim 6 , wherein the composition delivers the 3-HB to the large intestine, an anaerobic section of the large intestine, the colon, the terminal ileum, or a combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2019
From: BRADLEY, BENJAMIN; GREEN, EDWARD; HEEG, DANIELA
To: CHAIN BIOTECHNOLOGY LIMITED
Reel/Frame 048800/0666 →
Priority Claims (2)
GB 1616058 · Sep 21, 2016 · national
GB 1706751 · Apr 27, 2017 · national
Continuity (1)
Related Publication 20200030266A1 · Jan 30, 2020
Cited By (2)
US 12,589,119 US 12,648,968